Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

Syros stocks jumps in first day of trading

By , Globe Staff

The Cambridge company, which is developing drugs to regulate the genes that cause cancers and other diseases, raised $50 million in an initial public offering.

Tesaro investors have a $1.8 billion day

By , Globe Staff

The Waltham company reported its experimental drug slowed ovarian cancer progression in a late-stage clinical trial.

Moderna gets $200m in expanded Merck deal

By , Globe Staff

The cash will help the Cambridge-based biotech accelerate a portfolio of experimental drugs through research and development and help finance a manufacturing site.

Infinity Pharma cuts 100 jobs after AbbVie deal is terminated

By , Globe Staff

The layoffs are on top of 46 jobs eliminated after the Cambridge company released disappointing clinical results for an experimental drug.